Collegium Pharmaceutical, Inc. announced the execution of a Master Settlement Agreement resolving all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisions in the United States on March 18, 2022. The execution of this Master Settlement Agreement represents the implementation of a previously announced settlement framework with these parties in December 2021. As part of the Master Settlement Agreement, the Company paid $2.75 million to the plaintiffs and the cases will be dismissed, with prejudice, in the coming weeks. The Company entered into the Master Settlement Agreement to efficiently resolve this litigation without an admission of liability or wrongdoing.
“We are pleased at the resolution of Collegium’s opioid-related litigation,” said Shirley Kuhlmann, EVP, General Counsel and Chief Administrative Officer of Collegium. “This is an important step for our organization as we continue to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!